Rapid Identification of a Novel Small Molecule Phosphodiesterase 10A (PDE10A) Tracer
Citations Over TimeTop 10% of 2012 papers
Abstract
A radiolabeled tracer for imaging therapeutic targets in the brain is a valuable tool for lead optimization in CNS drug discovery and for dose selection in clinical development. We report the rapid identification of a novel phosphodiesterase 10A (PDE10A) tracer candidate using a LC-MS/MS technology. This structurally distinct PDE10A tracer, AMG-7980 (5), has been shown to have good uptake in the striatum (1.2% ID/g tissue), high specificity (striatum/thalamus ratio of 10), and saturable binding in vivo. The PDE10A affinity (K(D)) and PDE10A target density (B(max)) were determined to be 0.94 nM and 2.3 pmol/mg protein, respectively, using [(3)H]5 on rat striatum homogenate. Autoradiography on rat brain sections indicated that the tracer signal was consistent with known PDE10A expression pattern. The specific binding of [(3)H]5 to rat brain was blocked by another structurally distinct, published PDE10A inhibitor, MP-10. Lastly, our tracer was used to measure in vivo PDE10A target occupancy of a PDE10A inhibitor in rats using LC-MS/MS technology.
Related Papers
- → Increased social interaction in mice deficient of the striatal medium spiny neuron‐specific phosphodiesterase 10A2(2007)93 cited
- → Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A(2009)51 cited
- → Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia(2007)19 cited
- → cGMP-Binding Phosphodiesterase: Novel Effects of cGMP Binding on the Interaction Between Functional Domains in the Enzyme(1990)
- → A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesia in Parkinsonian Monkeys(2018)